Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations (Tables)

Organization and Nature of Operations (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Schedule of company's subsidiaries consolidated financial statements
Name of Subsidiary   Place and date of Incorporation   Percentage of Ownership   Principal Activities

Avalon Healthcare System, Inc.




May 18, 2015

  100% held by AVCO   Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (“USA”)

Avalon (BVI) Ltd.

(“Avalon BVI”)


British Virgin Island

January 23, 2017

  100% held by AVCO  


is in process of being dissolved


Avalon RT 9 Properties LLC

(“Avalon RT 9”)


New Jersey

February 7, 2017

  100% held by AVCO   Owns and operates an income-producing real property and holds and manages the corporate headquarters

Avalon (Shanghai) Healthcare Technology Co., Ltd.

(“Avalon Shanghai”)



April 29, 2016

  100% held by AHS   Provides medical related consulting services

Genexosome Technologies Inc.




July 31, 2017

  60% held by AVCO   Dormant

Avactis Biosciences Inc.




July 18, 2018

  60% held by AVCO   Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers

International Exosome Association LLC




June 13, 2019

  100% held by AVCO   Promotes standardization related to exosome industry